Claudia Stancanelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5889436/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
2	Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	118
3	Psychosocial impact of sport activity in neuromuscular disorders. Neurological Sciences, 2020, 41, 2561-2567.	1.9	8
4	Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurological Sciences, 2019, 40, 661-669.	1.9	32
5	Are novel outcome measures for Charcot–Marie–Tooth disease sensitive to change? The 6-minute walk test and StepWatchâ,,¢ Activity Monitor in a 12-month longitudinal study. Neuromuscular Disorders, 2019, 29, 310-316.	0.6	6
6	6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscular Disorders, 2019, 29, 213-220.	0.6	14
7	Unilateral hyperhidrosis as persistently isolated feature of syringomyelia and Arnold Chiari type 1. Neurological Sciences, 2018, 39, 1607-1608.	1.9	3
8	Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. European Journal of Human Genetics, 2017, 25, 1055-1060.	2.8	23
9	Phenotypic variability of TTR Val122Ile mutation: a Caucasian patient with axonal neuropathy and normal heart. Neurological Sciences, 2017, 38, 525-526.	1.9	15
10	Novel outcome measures for Charcotâ^'Marieâ^'Tooth disease: validation and reliability of the 6â€min walk test and StepWatch ^{â,,¢} Activity Monitor and identification of the walking features related to higher quality of life. European Journal of Neurology, 2016, 23, 1343-1350.	3.3	26
11	Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy. Neuromuscular Disorders, 2016, 26, 374-377.	0.6	13
12	Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Journal of Neurology, 2016, 263, 916-924.	3.6	76
13	A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 620-627.	1.9	52
14	Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area. Journal of Neuromuscular Diseases, 2015, 2, S39-S48.	2.6	67
15	Charcot–Marie–Tooth 2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a multigenerational family. Neurological Sciences, 2015, 36, 1003-1006.	1.9	18
16	Considerable post-partum worsening in a patient with CMT2E. Neurological Sciences, 2013, 34, 1813-1814.	1.9	1
17	Autonomic Involvement in Subacute and Chronic Immune-Mediated Neuropathies. Autoimmune Diseases, 2013, 2013, 1-7.	0.6	6
18	Transthyretinâ€related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset. Journal of the Peripheral Nervous System, 2012, 17, 385-390.	3.1	41

#	Article	IF	CITATIONS
19	Unusual features of central nervous system involvement in <scp>CMTX</scp> associated with a novel mutation of <scp><i>GJB1</i></scp> gene. Journal of the Peripheral Nervous System, 2012, 17, 407-411.	3.1	13
20	Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A. Muscle and Nerve, 2012, 45, 451-452.	2.2	10
21	Endocardial and Epicardial Deformations in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. Circulation Journal, 2011, 75, 1200-1208.	1.6	54